Biomarin Pharmaceutical Inc. Earnings

Biomarin Pharmaceutical Inc.’s revenue jumped 17.03% since last year same period to $874.57Mn in the Q4 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 12.68% jump in its revenue since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit fell -137.28% since last year same period to $-46.57Mn in the Q4 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated -51.49% fall in its net profits since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit margin fell -131.85% since last year same period to -5.33% in the Q4 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated -34.44% fall in its net profit margins since last 3-months.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.81 - a -1.19% fall from last quarter’s estimates.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at 0.81.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) fell -50% since last year same period to 0.46 in the Q4 2025. This indicates that the Biomarin Pharmaceutical Inc. has generated -50% annual rate of fall in its earning per share (EPS) in the last 4 quarters.